Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.

Who May Be Eligible (Plain English)

Who May Qualify: - All patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres are eligible to participate in this study - Must be able to schedule and tolerate additional PET/CT imaging following therapy - Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure. Who Should NOT Join This Trial: - Patients that are not candidates for Y90 radioembolization therapy - Patients that cannot tolerate additional imaging procedures following therapy - Patients that cannot tolerate the additional blood draws required for this study - Patients whose schedule does not allow them to remain at the hospital for the additional PET/CT imaging study Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * All patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres are eligible to participate in this study * Must be able to schedule and tolerate additional PET/CT imaging following therapy * Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure. Exclusion Criteria: * Patients that are not candidates for Y90 radioembolization therapy * Patients that cannot tolerate additional imaging procedures following therapy * Patients that cannot tolerate the additional blood draws required for this study * Patients whose schedule does not allow them to remain at the hospital for the additional PET/CT imaging study

Treatments Being Tested

DIAGNOSTIC_TEST

Post therapy PET/CT Imaging

whole-body PET/CT following Y90 radioembolization

Locations (1)

University of Tennessee Medical Center
Knoxville, Tennessee, United States